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Abstract
Human herpes virus-6 (HHV-6) and human herpes virus-7 (HHV-7) are immunomodulating viruses potentially affecting the nervous
system.We evaluated the influence of HHV-6 andHHV-7 infections on fibromyalgia (FM) clinical course. Forty-three FMpatients and
50 control group participants were enrolled. 39.50% (n= 17) FM patients had light A delta and C nerve fiber damage, 27.91% (n = 12)
had severe A delta and C nerve fiber damage. 67.44% (n = 29) FM patients had loss of warm sensation in feet, loss of heat pain
sensation, and increased cold pain sensation (34.90%, n = 15 in both findings). HHV-6 and HHV-7 genomic sequences in peripheral
blood DNA in 23/43 (51.00%) and 34/43 (75.50%) of samples from FM patients and in 3/50 (6.00%) and 26/50 (52.00%) of samples
from the control group individuals were detected. Active HHV-6 (plasma viremia) or HHV-7 infection was revealed only in FM
patients (4/23, 17.40% and 4/34, 11.80%, respectively). A statistically significant moderate positive correlation was found between A
delta and C nerve fiber damage severity and HHV-6 infection (p < 0.01, r= 0.410). 23/43 patients from the FM group and control
group participants HHV-6 and 34/45 HHV-7 did have infection markers. A statistically significant moderate positive correlation was
found betweenA delta and C nerve fiber damage severity andHHV-6 infection (p < 0.01, r= 0.410). No differencewas found between
detection frequency of persistent HHV-6 and HHV-7 infection between FM patients and the control group. Statistically significant
correlation was observed between quantitation of changes in QST thermal modalities and HHV-6 infection. There was no correlation
between A delta and C nerve fiber damage and HHV-7 infection.
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Introduction
Fibromyalgia (FM) is a chronic pain disorder with unknown
etiology which leads to disability and poor quality of life. The
main symptoms of FM are diffuse musculoskeletal pain, fa-
tigue, depression, sleepiness, emotional disturbance, and
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headache (Ballantyne et al. 2010; Lucas et al. 2006; Wolfe
et al. 2010). The disorder mainly affects middle-aged females
(Albin et al. 2008). The frequency of the disease increases
with age, as well as symptom severity and worsening of life
quality (Ballantyne et al. 2010; Balon and Wise 2015; Branco
et al. 2010; Jiao et al. 2014). The prevalence of FM in the
general population varies from 0.50 to 7.0% (Balon and
Wise 2015).
Diagnosis is clinical and is based on 1990 American
College of Rheumatology (ACR) diagnostic criteria (Hakim
et al. 2010). To set up FM diagnosis, patient must have diffuse
musculoskeletal pain which is presented daily for 3 months or
more, in areas on both sides of the body, both above and below
the waist, as well as in the spinal region, and on physical
examination at least 11 of possible 18 tender points should
be positive. All other possible reasons for pain have to be
excluded (Hakim et al. 2010; McCarberg and Clow 2009).
In 2010, ACR presented new preliminary FM diagnostic
criteria which may be easily used in primary care. The new
criteria include pain and somatic symptom assessment and
consider FM diagnosis, when fatigue and other somatic symp-
toms are more widely presented than pain. FM diagnosis is
probable if the widespread pain index is more than 7 from 19
possible and symptom severity scale is equal to or more than 5
from 12 possible, or if widespread pain index is from 3 to 6
and the symptom severity scale is equal to or more than 9
(Wolfe et al. 2010).
Despite the fact that FM etiology and pathogenesis remain
unclear (Albin et al. 2008), there is data that FM pain has a
neuropathic nature (Dworkin and Fields 2005; Martinez-
Livan 2012) and disease manifestation can follow after a spe-
cific trigger. A trigger could be a viral infection, such as hep-
atitis C (Kozanoglu et al. 2003; Mohammad et al. 2012; Rogal
et al. 2015), parvovirus B19 (Cassisi et al. 2011), human im-
munodeficiency virus (HIV) (Fox and Walker-Bone 2015;
Kole et al. 2013; Wiffen et al. 2013), and Epstein-Barr virus
(Buchwald et al. 1987). There is no data about the possible
role of human herpesvirus-6 (HHV-6) and human herpesvirus-
7 (HHV-7) infection in FM development (Berneman et al.
1992). HHV-6 and HHV-7 are immunomodulating and poten-
tially pathogenic to the nervous system and more than 90% of
adults have antibodies to these viruses. HHV-6 and HHV-7
infections alter the production of chemokines and cytokines,
which can significantly affect a normal immune response
(Lusso 2006). After the primary infection, viruses establish a
state of life-long, subclinical persistence, or latency
(Yoshikawa and Asano 2000) and can be reactivated in cases
of immunosuppression (Chan et al. 2001; Yao et al. 2010).
Although the sites of HHV-6 and 7 during latency are not
completely defined, it is known that HHV-6 can be found in
peripheral blood of seropositive adults, whereas HHV-7, by T
cell activation, can be reactivated from latently infected pe-
ripheral blood mononuclear cells (Kondo and Yamanishi
2007). Other human herpesviruses such as HSV-1 and HSV-
2 have been described in the involvement in chronic pain, but
have been connected to central nervous system involvement
(Vartiainen et al. 2009).
Studies which showed a reduction of dermal unmyelinated
nerve fiber bundles in skin samples of patients with FM, com-
paring with the control groups, support the assumption that
FM pain has a neuropathic nature (Uceyler et al. 2013).
Quantitative sensory testing (QST) methods are used to
evaluate the dysfunction of small fibers (Cruccu et al. 2010).
Thermal and mechanical incentives are used to measure dif-
ferent sensor thresholds that correspond to different receptors,
peripheral nerve fiber tips, and different CNS tracts (Hansson
et al. 2007). Abnormal test results indicate sensory tract dys-
function from receptor to sensory cortex (Shy et al. 2003).
Based on studies, QST can be used in cases of diabetic neu-
ropathy, small fiber neuropathy, toxic neuropathy, uremic neu-
ropathy, and other neuropathic pain syndromes (Shy et al.
2003), and probably to predict a response to treatment
(Gustorff et al. 2013). In all cases, QST results should be
interpreted together with a clinical pattern and another diag-
nostic test (EMG, nerve or skin biopsy, CT, MRI, etc.), be-
cause according to QST dates, it is not possible to determine
the level of dysfunction (Shy et al. 2003). The German
Research Network on Neuropathic pain has developed a stan-
dardized QST protocol which includes 13 parameters for ther-
mal, mechanical stimulus detection, and pain perception
(Rolke et al. 2006) and which analyses the functioning of A
beta, A delta, and C nerve fibers (Sydney and Conti 2011).
The assumption that FM pain has a neuropathic nature
increases the value of QST as an additional diagnostic tool.
Previous studies have shown the difference of thermal QST
results in FM patients, comparing with a control group, but the
results are heterogeneous (Blumenstiel et al. 2011; da Silva et al.
2013; Klauenberg et al. 2008; Pavlakovic and Petzke 2010;
Plauf et al. 2009; Tampina et al. 2012; Uceyler et al. 2013).
Methods
Population
The research group included 43 FM patients undergoing out-
patient treatment. The FM diagnosis was established based on
ACR 1990 and 2010 diagnostic criteria (Hakim et al. 2010;
McCarberg and Clow 2009; Wolfe et al. 2010).
Clinical signs were excluded from patients with previously
known polyneuropathy and other neurological diseases, in-
cluding lumbar and cervical radiculopathy. Patients did not
have type 1 or type 2 diabetes mellitus, toxic anamnesis
(e.g., alcohol or drug overuse), psychiatric disease, and acute
or chronic CMV, HCV, and HIV infection.
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From 43 patients included in the research, 42 were fe-
male and 1 was male with the average age 51.80 (min.
24 years, max. 72 years, SD ± 10.19) and mean duration
of diffuse pain—9.30 years (min. 1.5 months, max.
35 years, SD ± 10.20).
Research was reviewed and approved by Riga Stradins
University Ethics Committee.
Assessment of clinical symptoms
Patients were interviewed with several questionnaires to
evaluate the severity of their pain, their level of fatigue,
and the presence of other somatic symptoms, as well as
the disorder influence on the daily functioning and quality
of their lives.
Pain severity was estimated using 2010 ACR diagnostic
criteria widespread pain index with a maximum score of 19.
Symptom severity score apprises fatigue level, waking
unrefreshed, cognitive symptoms, and the presence of other
possible somatic symptoms, with maximal score 12 in total
(Wolfe et al. 2010).
In addition, chronic fatigue was estimated by the Fatigue
Severity Scale (FSS) with a maximum score of 63. Results
equal to or more than 36 indicate a presence of chronic fatigue
(Valko et al. 2008).
The influence of pain and other symptoms on daily function-
ing was measured using the Fibromyalgia Impact Questionnaire
(FIQ) with amaximum score of 100. Based on studies, a score of
around 50 corresponded to the average rating for a patient with
FM; a score above 70 indicated a severe course of the disease
(Assumpacao et al. 2010; Bennett 2005).
Quantitative sensory testing
From 13 QST parameters which were presented by the
German Research Network (Rolke et al. 2006), we used four
thermal detection thresholds for the perception of cold and
warm and thermal pain thresholds for cold and hot stimuli.
These parameters analyzed thinly myelinated A delta fibers,
and non-myelinated C fibers, which are responsible for pain
transmission and spinothalamic pathway (Rolke et al. 2006;
Sydney and Conti 2011). Sensory disturbances were exam-
ined in 43 patients using a PATHWAY device (Medoc Ltd.).
This device generates a defined and calibrated impulse within
certain limits (Cruccu et al. 2010). During the test, a probe was
attached to the skin of the patient that warmed or cooled it.
From the adapting temperature (32 °C), the probe started to
generate certain caliber thermal stimulus—temperature con-
tinuously rises or falls. The patient stops the stimulus rising (or
falling) when a predefined sensation (temperature perception
or temperature induced pain) is reached. The temperature dur-
ing the test can rise up to + 50 °C and fall down to + 20 °C. If
the maximum or minimum temperature limit is reached, the
device stops and returns to adapting the temperature. During
the test, patient cannot see the screen (Rolke et al. 2006).
Patients were tested on hand and foot dorsal surfaces: warm
and cold perception thresholds were measured four times each
in course, cold and heat pain perception thresholds were mea-
sured three times each in course.
Based on studies, handsweremore sensitive than feet for cold
and warm detection thresholds. In healthy subjects, mean warm
detection threshold varied from32.6 to 33.4 °C on the hand, from
33.7 to 36.4 °C on the foot, and the cold detection threshold was
around 31 °C on the hand and from 29.3 to 31.4 °C on the foot.
Studies did not show a significant difference between foot and
hand for heat-induced and cold-induced pain thresholds. The
mean heat-induced pain threshold in healthy subjects was around
43 °C and cold-induced pain threshold varies from 11.7 to
16.2 °C (Dyck et al. 1993; Hagander et al. 2000; Hansen et al.
1996). Cold-induced pain is the most variable modality which is
the most difficult to evaluate.
To compare a single patient’s QST data with group, mean
of age and gender matched healthy controls (HC), patients’
data were Z-transformed for each single parameter by using
the following expression: Z-score = (Meansingle patient −
Meancontrols) / SDcontrols.
Z-score value higher than 1.95 and lower than − 1.95 indi-
cates significant changes in thresholds comparing with the
control group. Z-score of zero represents a value correspond-
ing to the group mean of the HC subjects (Plauf et al. 2009).
Detection of HHV-6 and HHV-7 infection markers
The presence of persistent HHV-6 and/or HHV-7 infection
markers and infection activity phase was examined in all 43
patients with FM and 50 control group individuals.
Nested polymerase chain reaction (nPCR) was used to detect
viral genomic sequences in DNA isolated from a whole periph-
eral blood (WPB) (marker for persistent latent infection) and cell-
free blood plasma (marker of active infection). The total DNA
was isolated from WPB using the standard phenol-chloroform
extraction. The QIA amp DNA Blood Mini Kit was used to
extract DNA from plasma. To ensure the quality of the DNA, a
β-globin PCR was performed. nPCR amplification to detect the
presence of virus genomic sequences was carried out in the pres-
ence of 1 μg of WPB DNA and 10 μl of plasma DNA (corre-
sponding to 100 μl of plasma). HHV-6 and HHV-7 DNAwere
detected in accordancewith Secchiero et al. 1995 and Berneman,
Z.N., respectively. Positive controls (HHV-6 and HHV-7 geno-
mic DNA; ABI, Columbia, MD, USA) and negative controls
(DNA obtained from practically healthy HHV-6 and HHV-7
negative donors and reaction without template DNA), as well
as water controls, were included in each experiment. In our ex-
periments, the sensitivity of HHV-6-specific primers
corresponded to three copies of the HHV-6 genome and the
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sensitivity of HHV-7-specific primers to one copy of the HHV-7
per reaction (Tomsone et al. 2001; Kozireva et al. 2009).
Quantitative real-time polymerase chain
reaction
HHV-6 and HHV-7 loads were detected in all WPB DNA
samples positive for viral genomic sequences of the patients
with FM and control individuals using HHV-6 Real-TM
Quant kit (Sasace, Biotechnologies, Italy) and Realquality
RQ-HHV-7 kit (AB ANALITICA, Italy), and BioRad
CFX96 Real-time PCR System (BioRad, USA) according to
the manufacturers’ recommendations. The estimate of the me-
dian viral loads was carried out by taking into account the
nPCR results.
mRNA expression detection
RNA was isolated from peripheral blood mononuclear cells
(PBMC) (that was positive for HHV-6 and/or HHV-7 DNA) of
the patients with FM and control individuals using TRI Reagent
(Sigma-Aldrich), and cDNA synthesized using innuSCRIPT
One Step RT-PCR SyGreen Kit (Analytik Jena, Germany), ac-
cording to the manufacturers’ recommendations. Acquired
cDNA samples were used in PCR to detect HHV-6 U89/90
mRNA (regulatory immediate-early or α gene) and HHV-7
U57 mRNAs (coding the major capsid protein) expression.
Statistical analysis
All the graphs, calculations, and statistical analyses were per-
formed using GraphPad Prism software version 8.0 for Mac
(GraphPad Software, San Diego, CA, USA). To test whether
the collected numerical data are normally distributed, the
D’Agostino and Pearson, Anderson-Darling, and Shapiro-
Wilk normality tests were applied. Z-transformation of the
QST data was performed using the following expression
–Z ¼ x ¼ uð Þ/σ 푧=(푥− )/휎, where x 푥 corresponds to the
individual variable from the datasets that must be normalized
with z-transformation, whileμ휇 and σ휎 are the control group
mean and standard deviation (SD), respectively. Z-value equal
or higher than 2, also equal or lower than – 2, indicates that the
variable significantly differs from the control group mean. The
comparison of means between different groups of numerical
variables was performed using one-way ANOVA.
Homogeneity of variances was tested using Brown-Forsythe
and Bartlett’s tests, and in a case of unequal SDs, Brown-
Forsythe and Welch ANOVA tests were applied. If data were
not normally distributed, the comparison of medians between
different groups was switched to non-parametric one-way
ANOVA on ranks or Kruskal-Wallis test followed by two-
stage step-up method of Benjamini, Krieger, and Yekutieli as
post-hoc test. Because most of the data was distributed not
normally, results are expressed as median and interquartile
range (IQR) as dispersion characteristic, and p value less than
0.05 (p < 0.05) was considered as statistically significant.
Results
FM symptom presentation
More frequent areas of pain, assessed by the 2010 ACR FM
diagnostic criteria, were lower and upper parts of the back
(93% of 43) and shoulders (93% of 43). More than 80% of
43 patients reported pain in different parts of their legs, with
more than 70% in arms. Mean WPI was 12.30 from 19 pos-
sible (min. 3, max. 18, SD ± 3.60; p < 0.0001).
Assessed by the 2010 ACR FM diagnostic criteria symp-
tom severity score, more than 80% of all patients reported
thinking or remembering problems, muscle weakness, head-
ache, numbness, dizziness, insomnia, or nervousness. Fifty to
70% of all patients had frequent urination, hearing difficulties,
shortness of breath, pain/cramps in the abdomen, depression,
nausea, chest pain, blurred vision, fever, dry mouth, as well as
ringing in ears (dates of the frequency of somatic symptoms
are available in Table 1).
Table 1 Somatic symptom frequency assessed by 2010 ACR
diagnostic criteria (number of patients, percentage of all examined
patients)
Dry mouth 32 (71.1%) Frequent urination 26 (57.8%)
Pain in upper abdomen 21 (46.7%) Hives/welts 11 (24.4%)
Diarrhea 16 (35.6%) Ringing in ears 33 (73.3%)
Muscle weakness 39 (86.7%) Bladder spasms 11 (24.4%)
Headache 38 (84.4%) Muscle spasms 31 (68.9%)
Hearing difficulties 24 (53.3%) Dry eyes 19 (42.2%)
Raynauld’s 11 (24.4%) Pain/cramps in
abdomen
23 (51.1%)
Depression 34 (75.6%) Loss of appetite 17 (37.8%)
Constipation 15 (33.3%) Rash 11 (24.4%)
Dizziness 37 (82.2%) Vomiting 6 (13.3%)
Sun sensitivity 22 (48.9%) Hair loss 20 (44.4%)
Nausea 25 (55.6%) Heartburn 23 (51.1%)
Nervousness 39 (86.7%) Fever 29 (64.4%)
Chest pain 23 (51.1%) Numbness/tingling 39 (86.7%)
Remembering problems 40 (88.9%) Blurred vision 31 (68.9%)
Itching 21(46.7%) Oral ulcers 5 (11.1%)
Insomnia 38 (84.4%) Loss/change in taste 11 (24.4%)
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Accessed by the symptom severity score, all patients re-
ported fatigue. Twenty-two (51.20%) out of 43 patients
assessed their fatigue as being severe, pervasive, continuous,
and life disturbing; 20 (46.50%) patients described their fa-
tigue as being moderate, often presented and/or at a moderate
level, and only 1 (2.30%) patient described fatigue as being
slight. Mean symptom severity score was 8.10 out of 12 (min.
5, max. 12, SD ± 1.50; p < 0.0001).
Fatigue level was additionally evaluated using the FSS, 41
(95.30%) out of all patients had chronic fatigue, score more
than 36 (p < 0.0001); and 24 (8.7%) patients had the maxi-
mum score of 63. The mean score was 53.90 (min. 25, max.
63, SD ± 8.80; p < 0.0001).
Quality of life was assessed by FIQ. Seven (16.30%) pa-
tients scored quality of life less than 50, 22 (51.20%) out of 43
patients between 50 and 70, and 14 (32.5%) more than 70,
which indicates a severe course of the disease (p < 0.0001)
(Assumpacao et al. 2010; Bennett 2005). The mean score
was 64.7 out of 100 in total (min. 26, max. 95 SD ± 14.30);
(p < 0.0001).
Fig. 1 Cold sensation (a), cold
pain (b), warm sensation (c), and
heat pain (d) thresholds on hands
and feet in control subjects (ctrl)
and FM patients. Results are
displayed as combined box plot
(median and interquartile range
(IQR) as dispersion with Min to
Max bar) and scatter graph of
mean values from the
measurements on both hands or
feet. Fine dotted line shows
detection level
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Quantitative sensory testing
Quantitative sensory testing was performed on 43 patients. We
analyzed the average thermal QST results in feet and arms sepa-
rately because most small fiber neuropathies had occurred in a
length-dependent fashionandprimarilyaffected lowerextremities
(Hovaguimian andGibbons 2011; Themistocleus et al. 2014).
Eleven (25.60%) out of 43 patients had significant
hypoesthesia (reduced or partial loss of sensory function,
which means both cold and warm perception thresholds may
be increased) in feet, of which two patients also had significant
hypoesthesia in hands (cold perception threshold less than
27 °C). In 20 (46.50%) out of 43 patients, significant
hypoesthesia in feet was detected, in one (2.30%) patient,
there was significant hypoesthesia in hands (warm perception
thresholds more than 40 °C). None of the patients had
hypoesthesia in both their feet and hands.
In 28 (65.10%) out of 43 patients, significant hypoalgesia
in feet was detected, and in 24 (55.80%) out of 43 patients,
there was significant hypoalgesia in hands (heat pain threshold
more than 45 °C). In 21 (48.80%) out of 43 patients, heat
hypoalgesia in both hands and feet was detected, and only in
3 (7%) out of 43 patients, heat hypoalgesia was only in hands.
In 4 (9.30%) out of 43 patients, significant hyperalgesia in
hands, and in 2 (4.70%) of them, significant hyperalgesia in
feet was observed (heat pain threshold less than 40 °C).
Eventually, in 35 (81.40%) out of 43 patients, there was sig-
nificantly modified heat pain threshold in hands, in feet, or in
all tested surfaces. In 5 (11.60%) out of 43 patients, significant
cold hyperalgesia in feet was detected, and 3 (7%) out the 43
patients had also significant cold hyperalgesia in hands (cold
perception threshold more than 27 °C). In 22 (51.20%) out of
43 patients, a cold pain threshold of less than 20 °C was
observed in hands, and in 23 (53.50%) out of 43, in feet
(QST graphical representation available in Fig. 1).
In 4 (9%) out of 43 patients, no significant changes in any
thermal QST modality were observed; in 17 (39.50%) out of
43, significant changes in one thermal QST modality were
Fig. 2 Distribution of z-scores vs
control level in healthy subjects
(control) and FM patients. a Cold
sensation threshold. b Warm
sensation threshold. Z-values that
significantly differ are marked as
bold shape
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detected (in hands, in feet, or in both hands and feet), which
indicates on light A delta and C nerve fiber damage. In 10
(23.30%) out of 43 patients, there were significant changes in
two thermal QSTmodalities detected, which indicate on mod-
erate A delta and C nerve fiber damage. In 12 (27.90%) out of
43 patients, significant changes in three thermal QST modal-
ities were observed. None of the patients had significant
changes in all four thermal QST modalities. Changes in three
and more thermal QST modalities indicate on severe A delta
and C nerve fiber damage.
By analyzing z-score mean values, 29 (67.40%) out of 43
patients had loss of warm sensation in feet and 10 (23.30%)
out of 43 in hands, comparing with healthy controls. Fifteen
(34.90%) out of all patients had loss of heat pain sensation in
feet, and 13 (30.20%) loss of heat pain sensation in hands,
comparing with healthy controls. Two (4.70%) out of patients
had increased heat pain sensation in feet and 6 (14%) in-
creased pain sensation in arms, comparing with healthy
controls. In total, in comparison with the control group, 17
(39.50%) out of 43 patients had significant changes in heat
pain threshold in feet, and 19 (44.20%) significant changes in
heat pain threshold in hands. Thirteen (30.20%) patients had
loss of cold sensation in feet, and 2 (4.70%) loss of cold
sensation in hands, comparing with healthy control. Fifteen
(34.90%) out of 43 patients had increased cold pain sensation
in feet, and 13 (30.20%) increased cold pain sensation in
hands (a graphical representation of thermal QST threshold
changes in FM patients comparing with healthy control is
available in Figs. 2 and 3).
Detection of HHV-6 and HHV-7 infection
markers
Qualitative nPCR testing was performed on 43 patients.
Roseoloviruse genomic sequences were detected in 36 out of
Fig. 3 Distribution of z-scores vs
control level in healthy subjects
(control) and FM patients. a Cold
pain threshold. b Heat pain
threshold. Z-values that
significantly differ are marked as
bold shape
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43 (83.70%) FM patients DNAWPB samples versus 10 out of
20 (50%) control group individuals (p = 0.013). No difference
in frequency of single HHV-6 and single HHV-7 infection was
detected between FM patients (3/43, 7% and 19/43, 44.20%,
respectively) and control group individuals (1/20, 5% and 8/20,
40%, respectively). However, a significantly higher rate of con-
current (HHV-6 and HHV-7) infection was diagnosed in FM
patients in comparison with control group individuals (14/43,
32.60% versus 1/20, 5% respectively; p = 0.024).
Plasma viremia (a marker of active viral infection) was
revealed only in patients with FM (6/36, 16.70%). From them,
2/3 had single HHV-6, 2/19 single HHV-7, and 2/14
concurrent infection. In patients with concurrent infection,
both HHV-6 and HHV-7 DNA in plasma were detected.
Median HHV-6 and HHV-7 loads were higher inWPBDNA
samples in FM patients (815.8 [ranges from 1126.5 to 366.24]
and 311 [ranges from 435.8 to 63.3] copies/106 cells compared to
the control group individuals (125.5 [range 192.5–52.5] and
173.12 [range 281.37–66.73] copies/106 cells, respectively).
HHV-6 genomic sequences were detected in 23 out of 43
(51.10%) FM patients versus 3 out of 5 (6%) control group
individuals (p < 0.001). HHV-7 infection in FM patients and
control group individuals was 34 out of 43 (75.50%) and 26
out of 50 (52%); p = 0.020 respectively. HHV-6 plasma viremia
Fig. 4 Influence of HHV viral
infection on cold (a, b, c) and
warm (d, e, f) sensation
thresholds on hands and feet in
healthy subjects (control, ctrl) and
FM patients. −HHV, absent of
viral infection; HHV, viral
infection (type 6, type 7, or dual
6 + 7). Control group (a) is
represented by both −HHV
(filled symbol) and HHV (empty
symbol) subjects. Results are
displayed as median and
interquartile range (IQR) as
dispersion. Fine dotted line shows
detection level
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(a marker of active viral infection) was revealed only in patients
with FM (4/23, 17.40%) and HHV-7 in (4/34, 11.70%) patients.
Median HHV-6 and HHV-7 load levels were higher in FM pa-
tients [range 6104.2–67.16] and 583 [range 953–< 10] cop-
ies/106 cells, respectively, compared to the healthy individuals
(125.5 [range 192.5–52.5] and 181.52 [range 281.37–86.63]
copies/106 cells, respectively).
Relation between QST and the presence
of viral infection markers
To estimate correlation, QST results and the presence of viral
infection markers results were transformed. For QST, 0
indicated no changes in any modality, 1 - abnormal QST re-
sults in one modality, 2 - abnormal results in two modalities,
and 3 - abnormal results in three or more modalities. For the
presence of viral infection markers, 0 indicated that no viral
genomic sequences are presented, 1 - presence of latent virus
infection markers and 2 - presence of active virus infection
markers. Distribution of modalities with respect to FM and to
HHV infection can be seen in Fig. 8.
A statistically significant (p < 0.01) moderate positive cor-
relation (r = 0.410) was found between A delta and C nerve
fiber damage severity and HHV-6 infection, QST changes
were more significant in patients who had persistent HHV-6
infection in active or latent phase. We did not find any corre-
lation between A delta and C nerve fiber damage and the
Fig. 5 Influence of HHV viral
infection on cold (a, b, c) and heat
(d, e, f) pain thresholds on hands
and feet in healthy subjects
(control, ctrl) and FM patients. −
HHV, absent of viral infection;
HHV, viral infection (type 6, type
7, or dual 6 + 7). Control group
(a) is represented by both −HHV
(filled symbol) and HHV (empty
symbol) subjects. Results are
displayed as median and
interquartile range (IQR) as
dispersion. Fine dotted line shows
detection level
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presence of HHV-7 infection markers. There was also no cor-
relation between the presence of viral infection markers and
symptom severity according to the FIQ and 2010 ACR pre-
liminary diagnostic criteria for FM. The influence of HHV
viral infection on cold and warm sensation and pain threshold
is visually shown in Figs. 4 and 5. The influence of HHV viral
infection on the distribution of z-scores in the control group
and FM patients can be seen in Figs. 6 and 7.
Discussion
In this study, clinical characteristics of FM patients, man-
ifested by diffuse musculoskeletal pain and additional so-
matic symptoms like fatigue, sleepiness, emotional distur-
bance, depression, cognitive symptoms, gastrointestinal
symptoms, and headache, were described. Although in-
flammatory, autoimmune disorders, and infections have
been mentioned as etiological factors in FM development,
there are very little data supporting such hypothesis
(Borchers and Gershwin 2015). We did not review the
mechanism of action of nerve damage in patients with
FM and HHV infections because our main focus was on
the phenotypic aspect of the disease.
To evaluate peripheral nerve damage in FM patients
with HSV-6 and 7, quantitative sensory testing was per-
formed. The QST results of FM patients in all modalities
are shown to be more variable than in the control group.
We analyzed the average thermal QST results in feet and
arms separately because most small fiber neuropathies oc-
cur in a length-dependent fashion and primarily affect the
lower extremities (Hovaguimian and Gibbons 2011;
Themistocleus et al. 2014). FM patients demonstrated sig-
nificant differences in thermal QST parameters in compar-
ison with healthy controls.
Many previous studies have shown significant differ-
ences in thermal QST compared with a control group,
but the results differ. Some studies report increased
Fig. 6 Influence of HHV viral
infection on distribution of z-
scores in healthy subjects
(control) and FM patients. a Cold
sensation threshold. b Warm
sensation threshold. Z-values that
significantly differ are marked as
bold shape
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thermal sensitivity in FM patients while others find de-
creased thermal sensitivity in FM patients compared with
that in the control group (Klauenberg et al. 2008;
Pavlakovic and Petzke 2010; Plauf et al. 2009). For
warm perception, C fibers are responsible for deep and
burning pain, and A delta fibers for cold sensation and
sharp pain, which indicates light A delta and C nerve
fiber damage.
No data exist on the role of HHV-6 and HHV-7 infec-
tion in the development of FM, although HHV-6 and
HHV-7 are ubiquitous viruses with immunomodulating
properties and are potential pathogens to the nervous sys-
tem (Lusso 2006). In our research, we found nerve fiber
damage because of HHV-6; however, no correlation be-
tween A delta and C nerve fiber damage and HHV-7 in-
fection was found. An exact mechanism on how HHV-6
virus influenced the nervous system and why there was no
correlation between HHV-7 and nerve fiber damage was
not analyzed.
The results of our study show no difference in the detection
frequency of persistent infection between FM patients and
control group individuals; however, higher HHV-6 and
HHV-7 load, as well as infection in active phase, were detect-
ed only in patients with FM. Statistically significant (p < 0.01)
moderate positive correlation (r = 0.410) was observed be-
tween quantitation of changes in QST thermal modalities
and HHV-6 infection; QST changes were more significant in
patients who have persistent HHV-6 infection in an active or
latent phase.
In this study, we found that FM patients have a high
level of fatigue (based on the Fatigue Severity Scale and
2010 ACR diagnostic criteria for FM). This finding is
consistent with previous studies indicating that between
20 and 70% of FM patients also have chronic fatigue
syndrome according to the diagnostic criteria and be-
tween 35 and 70% patients with chronic fatigue syn-
drome correspond to FM diagnostic criteria (Aaron
et al. 2000).
Fig. 7 Influence of HHV viral
infection on distribution of z-
scores in healthy subjects
(control) and FM patients. a Cold
pain threshold. b Heat pain
threshold. Z-values that
significantly differ are marked as
bold shape
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Conclusions
There was a higher detection frequency of persistent
HHV-6 and HHV-7 infection in FM patients than in con-
trol group individuals. A higher HHV-6 and HHV-7 load
and infection in active phase was detected only in patients
with FM. Statistically significant correlation was observed
between quantitation of changes in QST thermal modali-
ties and HHV-6 infection. There was no correlation be-
tween A delta and C nerve fiber damage and HHV-7
infection.
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